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S1PR1 signaling has been shown to restrain the num-
ber and function of regulatory T (Treg) cells in the
periphery under physiological conditions and in coli-
tismodels, but its role in regulating tumor-associated
T cells is unknown. Here, we show that S1PR1
signaling in T cells drives Treg accumulation in tu-
mors, limits CD8+ T cell recruitment and activation,
and promotes tumor growth. T-cell-intrinsic S1PR1
affects Treg cells, but not CD8+ T cells, as demon-
strated by adoptive transfer models and transient
pharmacological S1PR1 modulation. An increase in
S1PR1 in CD4+ T cells promotes STAT3 activation
and JAK/STAT3-dependent Treg tumor migration,
whereas STAT3 ablation in T cells diminishes
tumor-associated Treg accumulation and tumor
growth. Our study demonstrates a stark contrast be-
tween the consequences of S1PR1 signaling in Treg
cells in the periphery versus tumors.INTRODUCTION
Regulatory T (Treg) cells are critical mediators in shaping the
immunological microenvironment in various diseases, including
cancer (Chaudhry and Rudensky, 2013; Mougiakakos et al.,
2010; Zou, 2006). In tumors, Treg cells accumulate and suppress
antitumor immunity by expressing anti-inflammatory cytokines
and coinhibitory molecules that modulate tumor cells and other
tumor-associated immune subsets (Darrasse-Je`ze et al., 2009;
Josefowicz et al., 2012; Me´ne´trier-Caux et al., 2012; Yamaguchi
and Sakaguchi, 2006). Although numerous studies have impli-
cated Treg cells in promoting cancer progression through multi-
ple mechanisms (Me´ne´trier-Caux et al., 2012; Nishikawa and
Sakaguchi, 2010), the signaling mediators that regulate their
accumulation and function in tumors have yet to be fully
explored. Recently, several chemokine-signaling axes have
been shown to mediate Treg recruitment to tumors (Mailloux
and Young, 2010; Nishikawa and Sakaguchi, 2010). In addition
to G protein coupled receptor (GPCR) chemokine receptors,992 Cell Reports 6, 992–999, March 27, 2014 ª2014 The Authorssphingosine-1 phosphate receptors (S1PR1–S1PR5) are also
important regulators of immune cells, including T cells (Arnon
et al., 2011; Rivera et al., 2008; Spiegel and Milstien, 2011), but
their impact on tumor-associated T cells remains to be directly
investigated.
The roles of S1PR1 inmigration and activation of specific T cell
subsets have been somewhat controversial. Early studies impli-
cated S1P and S1PR1 in regulating the differentiation of Th2,
Treg, and Th17 cells, while limiting Th1 cells (Goetzl et al.,
2008). More recent studies have demonstrated that S1PR1
restrains thymic development of Treg cells, their peripheral
numbers, and their suppressive functions (Liu et al., 2009). In
mice with S1pr1 ablation in T cells, Treg populations in lymphoid
tissues are enhanced with elevated suppressive activity (Liu
et al., 2009, 2010). Conversely, in mice with T cells overexpress-
ing S1pr1, Treg cells are blunted in lymphoid tissues and in the
colon, whereas Th1 subsets are increased, making them partic-
ularly susceptible to colitis in adoptive transfer models (Liu et al.,
2009, 2010). S1P and S1PR1 are also important mediators of
cancer progression (Spiegel and Milstien, 2011). However,
whether S1PR1 promotes or inhibits tumor Treg cells remains
to be addressed. In the current study using mice with S1pr1
overexpression or deletion specifically in T cells as well as tran-
sient pharmacological S1PR1 modulation, we show that S1PR1
signaling regulates the accumulation of Treg cells in tumors,
limits CD8+ T cell infiltration and function, and promotes tumor
growth. Furthermore, we find that S1PR1-mediated tumor
accumulation of Treg cells requires JAK/STAT3 signaling. These
findings suggest that modulation of S1PR1-JAK/STAT3 sig-
naling in Treg cells may have significant effects on the tumor
microenvironment with potential immunotherapeutic implica-
tions in cancer.
RESULTS AND DISCUSSION
T Cell S1PR1 Signaling Promotes Tumor Accumulation
of Treg Cells
To investigate whether S1PR1 regulates Treg accumulation in
tumors, E0771 breast carcinoma cells were orthotopically im-
planted in wild-type (WT) (S1pr1+/+) and T cell S1pr1-deficient
(S1pr1/) mice, and Treg cells were assessed in primary tu-
mors, spleens, and tumor-draining lymph nodes (TDLN). Genetic
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Figure 1. T Cell S1PR1 Signaling Promotes Tumor Accumulation of Treg Cells
(A) Foxp3+ of CD4+ T cells in the tumor, tumor-draining lymph node (TDLN), and spleen of E0771 tumor-bearing S1pr1+/+ and S1pr1/mice. Representative flow
cytometry images (top) and quantification of n = 4 per group (bottom).
(B) Foxp3+ of CD4+ T cells in the tumor, TDLN, and spleen of E0771 tumor-bearingWT and S1pr1-Tgmice. Representative flow cytometry (top) and quantification
of n = 3 per group (bottom).
(C) Foxp3+ of CD4+ T cells in E0771 tumor-bearing mice treated for 24 hr with either vehicle control (2.5% DMSO in PBS) or 50 mg FTY720. Representative flow
cytometry images (top) and quantification of nR 3 per group (bottom). PB, peripheral blood.
(D) Tumor-infiltrating CD8+ and Foxp3+CD4+ T cells in MB49 tumor-bearing Rag2/mice reconstituted withWT (CD45.1) and S1pr1-Tg (CD45.2) splenic T cells.
Quantification of n = 2 per group.
(E) CD4+ T cells (left) and Foxp3+ of CD4+ T cells in the tumor, TDLN, and spleen (right) in B16 tumor-bearing Rag1/ mice reconstituted with WT or S1pr1-Tg
CD4+ T cells. n = 6 per group.
(F) Ki67 and annexin V (Ann-V) expression in tumor-associated Treg cells of B16 tumor-bearing WT and S1pr1-Tgmice. Representative flow cytometry images of
Ki67 (top) and quantification of nR 4 per group (bottom). All data shown above are representative of at least two independent experiments.ablation of S1pr1 in T cells promoted Treg development in
lymphoid tissues, with a significant increase in Foxp3+ Treg cells
found within the CD4+ T cell compartment in spleens and TDLN
of tumor-bearing mice (Figure 1A), corroborating previous find-
ings under non-tumor-bearing conditions (Liu et al., 2009). Inter-
estingly, Treg cells were dramatically reduced in tumors by
S1pr1 ablation in T cells (Figure 1A). Blockade of tumor accumu-lation of Treg cells in S1pr1/ mice was also confirmed in the
B16 melanoma model (Figure S1A).
Although the use of T cell-S1pr1-deficient mice demonstrated
a requirement for S1PR1 in Treg accumulation in tumors, S1PR1
is known to be crucial for thymic egress of T cells and therefore its
genetic ablation leads to systemic lymphopenia (Matloubian
et al., 2004). Thus, we employed T cell S1pr1-transgenic miceCell Reports 6, 992–999, March 27, 2014 ª2014 The Authors 993
(S1pr1-Tg) (Gra¨ler et al., 2005) to confirm our findings in tumor
models. Overexpression of S1pr1 in T cells promoted Treg accu-
mulation in E0771 andB16 tumors (Figures 1B and S1B). Of note,
total CD4+ T cell percentages in tumors remained unchanged
(WT: 3.1% ± 0.3%; S1pr1-Tg: 3.4% ± 0.6%). CD25 was widely
expressed by tumor-associated Treg cells from WT and S1pr1-
Tgmice (FigureS1C).Althoughprior studiesdemonstrateddimin-
ished Treg numbers in lymphoid tissue of S1pr1-Tg mice, pro-
cancer systemic effects in E0771 and B16 tumor-bearing mice
may have counteracted the diminishing Treg cells in lymphoid
organs, as we observed little effect on Treg cells in TDLN and a
slight increase in splenic Treg cells in S1pr1-Tg mice compared
with control mice (Figures 1B and S1B). Taken together, our find-
ings are consistent with prior studies demonstrating that S1PR1
restrains Treg numbers in the periphery (Liu et al., 2009). How-
ever, within the primary tumor, S1PR1 signaling is critical for
Treg accumulation, which highlights a stark contrasting role of
S1PR1 in regulating peripheral and tumor-associated Treg cells.
To further substantiate the regulation of tumor accumulation of
Treg cells by S1PR1, we used a pharmacologic approach with
the S1PR1 immunomodulator, FTY720 (Mandala et al., 2002).
Mice bearing established E0771 tumors were treated systemi-
cally with vehicle control or FTY720 for 24 hr prior to evaluating
Treg cells in various tissues. There was an expected reduction
of total CD4+ and CD8+ T cells in peripheral blood of FTY720-
treated mice compared with control mice (Figures S2A and
S2B). However, total CD4+ and CD8+ T cells percentages in
tumors, spleens, and TDLN remained unchanged (Figures S2A
and S2B). We showed a significant reduction in tumor accumu-
lation of Treg cells, with an increased trend of Treg cells in
peripheral blood following transient FTY720 treatment (Fig-
ure 1C), suggesting a block in blood-to-tumor Treg recruitment.
This short-term treatment strategy could have important thera-
peutic implications, where transient modulation of S1PR1 may
prime the tumor microenvironment by inhibiting Treg cells to
allow for more potent antitumor immunity in combination with
other treatment approaches, such as adoptive T cell immuno-
therapy (Chen et al., 2007; Zou, 2006).
We further evaluated the importance of S1PR1 in the tumor
accumulation of T cells by coadoptively transferring WT
(CD45.1) and S1pr1-Tg (CD45.2) splenic T cells into Rag1/
mice, generating ‘‘chimeric’’ mice, which were then challenged
with B16 melanoma tumors. Overexpression of S1pr1 in T cells
significantly promoted tumor accumulation of Treg cells, while
showing a minimal effect on CD8+ T cells in tumors (Figure 1D).
To address the specific impact of S1PR1 signaling on the recruit-
ment of CD4+ T cells to tumors, WT or S1pr1-Tg CD4+ T cells
were transferred into Rag1/ mice. Although total CD4+
T cells in tumorswere similar in both groups, tumor accumulation
of Treg cells was increased inS1pr1-Tg chimeras comparedwith
WT chimera mice (Figure 1E). The adoptive transfer model
further confirmed that systemic cancer effects may override
the S1PR1-mediated restrain on Treg cells in peripheral tissues,
as Treg populations were relatively unaffected in spleens and
TDLN by overexpression of S1pr1. To determine whether
increased Treg cells in tumors was due to local expansion or
recruitment, we assessed proliferation and apoptosis markers
in tumor-associated Treg cells by flow cytometry. We found994 Cell Reports 6, 992–999, March 27, 2014 ª2014 The Authorsthat there were no discernible differences in Ki67 or annexin V
expression in Treg cells fromWT and S1pr1-Tgmice (Figure 1F),
suggesting that recruitment rather than local expansion of Treg
cells is crucially regulated by S1PR1 signaling.
S1PR1 Inhibits CD8+ T Cell Accumulation and Activity in
Tumors
We next assessed whether increased accumulation of Treg cells
in tumors by S1PR1 signaling impacts antitumor immunity.
Although, we observed no impact of S1PR1 in CD8+ T cells in
tumors in the coadoptive transfer system (Figure 1D), we demon-
strated a significant reduction in CD8+ T cells in E0771 tumors of
S1pr1-Tg mice compared with WT mice (Figure 2A), which was
associated with increased tumor-associated Treg cells. We
observed similar findings in the B16 tumor model (Figure S3A).
Importantly, TDLN showed no differences in CD8+ T cells,
although spleens showed a modest but significant increase in
S1pr1-Tgmice compared with WT control mice (Figure 2A).
To assess the activation status of tumor-associated CD8+
T cells, we analyzed their intracellular levels of interferon g
(IFNg) by flow cytometry. IFNg+CD8+ T cells were reduced in
E0771 and B16 tumors from mice with T cell overexpression of
S1pr1 compared with control mice (Figures 2B and S3B). We
also observed similar reductions in IFNg production in TDLN-
associated CD8+ T cells (Figure S3C), in contrast to earlier find-
ings in naive non-tumor-bearing mice (Liu et al., 2010). RT-PCR
analysis of fluorescence-activated cell sorting (FACS)-sorted
tumor-associated CD8+ T cells confirmed their reduced IFNg
expression (Figure S3D). Granzyme B expression in CD8+
T cells, as a measure of their cytotoxic function, demonstrated
a significant reduction in S1pr1-Tg mice compared with WT
mice (Figure 2C). We also observed a dramatic reduction in the
activation marker, CD69, in tumor-associated CD8+ T cells
from S1pr1-Tg mice (Figure 2D). Correlating with their reduced
activation state, CD8+ T cells from S1pr1-Tg mice showed
increased CD62L expression (Figure 2E), a naive T cell marker.
Although prior studies suggested that S1PR1 expression pro-
motes IFNg production in CD8+ T cells (Liu et al., 2010), we
showed that, in tumor models, S1PR1 negatively regulated
IFNg production. Additionally, we found decreased proliferation
and increased apoptosis of tumor-associated CD8+ T cells in
S1pr1-Tg mice compared with WT mice (Figure 2F), suggesting
local tumor inhibition.
To determine whether S1PR1 intrinsic to CD8+ T cells controls
their recruitment and activity in tumors, we adoptively trans-
ferred splenic CD8+ T cells from WT and S1pr1-Tg mice into
Rag1/ mice. Tumor infiltration of CD8+ T cells was unaffected
by S1pr1 overexpression (Figure 2G). In addition, IFNg-produc-
ing CD8+ T cells in tumors and spleens were also unaffected,
although we noted increased IFNg production by CD8+ T cells
in TDLN (Figure 2G). Collectively, we have demonstrated that,
although S1PR1 signaling had a dramatic impact on the tumor
infiltration and function of CD8+ T cells, this effect was not intrin-
sically regulated by S1PR1 signaling in CD8+ T cells but likely
mediated through S1PR1-induced Treg accumulation in tumors.
Further studies are warranted to elucidate the critical chemo-
kine-signaling mediators that are a requirement for direct CD8+
T cell recruitment to tumors.
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Figure 2. S1PR1 Inhibits CD8+ T Cell Accu-
mulation and Activity in Tumors
(A) CD3+ CD8+ T cells in the tumor, TDLN, and
spleen of E0771 tumor-bearing WT and S1pr1-Tg
mice. Representative flow cytometry images (top)
and quantification of n = 4 per group (bottom).
(B) IFNg+ tumor-infiltrating CD8+ T cells in E0771
tumor-bearing WT and S1pr1-Tg mice. Repre-
sentative flow cytometry images (left) and quanti-
fication of n = 3 per group (right).
(C) Granzyme B+ tumor-infiltrating CD8+ T cells in
E0771 tumor-bearing WT and S1pr1-Tg mice.
Representative flow cytometry images (left) and
quantification of n = 4 per group (right).
(D) CD69+ tumor-infiltrating CD8+ T cells in E0771
tumor-bearing WT and S1pr1-Tg mice. Repre-
sentative flow cytometry images (left) and quanti-
fication of n = 4 per group (right).
(E) CD62L+ tumor-infiltrating CD8+ T cells in E0771
tumor-bearing WT and S1pr1-Tg mice. nR 4 per
group.
(F) Ki67 and Ann-V expression in tumor-associ-
ated CD8+ T cells of B16 tumor-bearing WT and
S1pr1-Tg mice. Representative flow cytometry
images of Ki67 (left) and quantification of nR 4 per
group (right).
(G) Tumor-infiltrating CD8+ T cells (left) and IFNg+
CD8+ T cells in the tumor, TDLN, and spleen (right)
of B16 tumor-bearing Rag1/ mice reconstituted
withWT or S1pr1-Tg CD8+ T cells. n = 6 per group.
All data shown above are representative of at least
two independent experiments.S1PR1 in Treg Cells Promotes Tumor Growth
The ability of S1PR1 to promote tumor accumulation of Treg cells
and inhibit CD8+ T cells prompted us to assess how S1PR1
signaling in T cells ultimately affects tumor growth. We observed
significant tumor growth inhibition in S1pr1/ mice compared
with S1pr1+/+ mice bearing E0771 tumors (Figure 3A) or B16 tu-
mors (Figure 3B). Likewise, S1pr1-Tg mice showed significantly
increased tumor growth kinetics compared withWT control mice
(Figures 3C and 3D). To distinguish the potential contribution of
CD4+ and CD8+ T cells to tumor development, we measured
tumor growth in Rag1/ mice adoptively transferred with WT
or S1pr1 overexpressing CD4+ or CD8+ T cells. Rag1/ mice
adoptively transferred with S1pr1-Tg CD4+ T cells showed
significantly increased tumor growth compared with WT CD4+
T-cell-transferred mice (Figure 3E), whereas we observed no dif-
ferences in tumor growth kinetics in Rag1/ mice adoptively
transferred with S1pr1-Tg CD8+ T cells (Figure 3F), suggesting
that the overall impact of S1pr1 expression in T cells on tumor
growth is primarily contributed by Treg cells.Cell Reports 6, 992–99S1PR1-Mediated Tumor
Accumulation of Treg Cells
Requires JAK/STAT3 Signaling
Multiple studies have also implicated
STAT3 activation in driving tumor-
associated Treg cells by regulating their
numbers and suppressive activities in tu-
mors (Fujita et al., 2008; Kortylewski et al.,2009; Kujawski et al., 2010; Pallandre et al., 2007; Wei et al.,
2013; Yu et al., 2007, 2009). To determine whether STAT3
signaling may be involved in S1PR1-mediated Treg accumula-
tion in tumors, we first assessed phosphorylated STAT3
(pSTAT3; STAT3Y705) levels in T cells of tumor-bearing mice.
Tumor-infiltrating Treg cells showed moderately higher pSTAT3
levels in S1pr1-Tg mice (mean fluorescence intensity [MFI]:
2,870) compared with WT mice (MFI: 2,470) by flow cytometry
(Figure 4A). Western blotting further demonstrated elevated
STAT3 activation in tumor-associated CD4+ T cells in S1pr1-Tg
mice compared with WT mice (Figure 4B). S1pr1 expression
was also assessed by RT-PCR in tumor-associated WT and
S1pr1-Tg Treg cells from these mice (Figures S3E and S3F).
Our previous studies demonstrated persistent STAT3 activation
by S1PR1 in tumor cells and in tumor-associated myeloid
cells (Deng et al., 2012; Lee et al., 2010). To mimic this phenom-
enon in vitro, we stimulated T cells with tumor-derived factors
derived ex vivo from B16 tumors grown in C57BL/6 mice. B16
tumor-conditioned media (TCM) induced STAT3 activation in9, March 27, 2014 ª2014 The Authors 995
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Figure 3. S1PR1 in Treg Cells Promotes Tumor Growth
(A–D) Tumor growth kinetics of E0771 (A) and B16 (B) tumor-bearing S1pr1+/+ andS1pr1/mice. n = 3 per group. Tumor growth kinetics of E0771 (C) and B16 (D)
tumor-bearing WT and S1pr1-Tg mice. nR 4 per group.
(E) B16 tumor growth in Rag1/ mice reconstituted with WT or S1pr1-Tg CD4+ T cells. n = 6 per group.
(F) B16 tumor growth in Rag1/mice reconstituted with WT or S1pr1-Tg CD8+ T cells. n = 6 per group. All data shown above are representative of at least two
independent experiments.CD4+ T cells, which was elevated by S1pr1 overexpression (Fig-
ure 4C). Conversely, TCM failed to induce STAT3 activation in
S1pr1/CD4+ T cells compared with controls (Figure 4D). Over-
all, these findings support a link between S1PR1 and STAT3 in
T cells and that STAT3 activation in tumor-associated Treg cells
is potently regulated by S1PR1 signaling.
Our recent studies indicate that S1PR1 activates STAT3
signaling through JAK2 (Lee et al., 2010). Thus, we next evalu-
ated whether tumor-induced factors that recruit Treg cells
require S1PR1-JAK/STAT3 signaling using an in vitro cell migra-
tion system. Although TCMmodestly induced conventional T cell
(Tconv) migration in vitro, TCM induced Treg migration (Fig-
ure 4E), supporting the high Treg/Tconv ratio in tumors in vivo.
Importantly, Treg cells from S1pr1-Tg mice migrated signifi-
cantly more toward TCM compared with WT Treg cells (Fig-
ure 4F), whereas Tconv cells, but not Treg cells, migrated toward
exogenous S1P (Figures S4A and S4B). To further investigate
potential mechanisms involved in S1PR1-dependent Treg
migration toward tumor-derived factors, we reduced lipid levels
by using charcoal-stripped TCM. Lipid-depleted TCM failed to
induce Treg migration, which was not restored by only adding
exogenous S1P (Figure S4C). These data suggest that
S1PR1-induced Treg migration toward TCM may require other
lipid-signaling mediators, in addition to S1P, although further
investigation is warranted. WT and S1pr1-Tg Treg migration
toward TCM was nearly completely abrogated with the JAK in-
hibitor AZD1480 (Hedvat et al., 2009; Figure 4F), highlighting a
central role for JAK/STAT3 signaling in S1PR1-mediated recruit-
ment of Treg cells to tumors.996 Cell Reports 6, 992–999, March 27, 2014 ª2014 The AuthorsTo further validate the role of STAT3 signaling in S1PR1-medi-
ated tumor recruitment of Treg cells in vivo, we utilized the
adoptive transfer system to generate chimeric mice with WT-
or S1pr1-overexpressing CD4+ T cells, with intact or deficient
Stat3. In this adoptive transfer system, whereas T cell-Stat3
itself had little effect on Treg accumulation in tumors, ablating
Stat3 in T cells completely blocked the increased Treg accumu-
lation by overexpression of S1pr1 (Figure 4G). This effect on
Treg recruitment was specific to tumors, given that there were
little changes in splenic or TDLN-associated Treg cells in either
WT or S1pr1-Tg chimeric mice by ablating Stat3. Furthermore,
ablating Stat3 in T cells also inhibited the tumor-promoting
effects of S1pr1 overexpression in these mice (Figure 4H). Of
note, tumors’ growth trended higher in mice adoptively trans-
ferred with Stat3/ CD4+ T cells compared with WT chimeric
mice, but these mice did not show enhanced growth with over-
expression of S1pr1 in CD4+ T cells. This phenomenon was
likely due to a slight defect in homeostatic proliferation of
CD4+ T cells by Stat3 ablation (Durant et al., 2010), thus affecting
reconstituted CD4+ T cell numbers and corresponding tumor
growth kinetics in these mice. In summary, we have demon-
strated that S1PR1 signaling in T cells is critical for the tumor
accumulation of Treg cells, limiting CD8+ T cell infiltration and
activation, and regulating tumor growth. Importantly, S1PR1 is
a GPCR, which is more readily targetable than transcription
factors, such as STAT3. Overall, these studies may provide
insight into targeting strategies to modulate the Treg-induced
immunosuppressive tumor microenvironment for improving
cancer immunotherapies.
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Figure 4. S1PR1-Mediated Treg Tumor Accumulation Requires JAK/STAT3 Signaling
(A) Flow cytometry analysis of pSTAT3 (STAT3Y705) levels in tumor-associated CD4+ Foxp3+ T cells in E0771 tumor-bearing WT and S1pr1-Tg mice.
(B) Western blotting of pSTAT3 and S1PR1 expression in TDLN and tumor-associated CD4+ T cells enriched from B16 tumor-bearing WT and S1pr1-Tg mice.
(C and D) Western blotting of pSTAT3 and S1PR1 expression in splenic CD4+ T cells enriched from B16 tumor-bearing WT and S1pr1-Tg mice (C) or from B16
tumor-bearing S1pr1+/+ andS1pr1/mice (D) stimulatedwith or without B16 TCM. All western blotting data shown are representative of at least two independent
experiments.
(E) In vitro migration of WT splenic Foxp3CD4+ (Tconv) and Foxp3+CD4+ (Treg) T cells toward media or 20% B16 TCM. Flow cytometry analysis of migrated
CD4+ T cells (left) and quantification of migration (right). n = 3 per condition. Data shown are representative of at least three independent experiments.
(F) In vitro migration of WT and S1pr1-Tg splenic Treg cells toward media or 20% B16 TCM, in the presence or absence of 5 mM AZD1480. n = 3 per condition.
Data shown are representative of two independent experiments.
(G) Foxp3+ of CD4+ T cells in the tumor, TDLN, and spleen of B16 tumor-bearing Rag1/mice reconstituted with WT, S1pr1-Tg, Stat3/, or S1pr1-Tg/Stat3/
CD4+ T cells. n = 6 per group.
(H) Endpoint B16 tumor volumes inRag1/mice reconstituted withWT, S1pr1-Tg, Stat3/, or S1pr1-Tg/Stat3/CD4+ T cells. n = 6 per group. Data shown are
representative of two independent experiments.EXPERIMENTAL PROCEDURES
Mice
S1pr1loxp/loxp mice were kindly provided by Dr. Richard Proia (National Insti-
tutes of Health) and crossed with CD4-Cre mice (Taconic) to generate S1pr1
deletion in T cells (S1pr1/). Stat3loxp/loxp mice were kindly provided by
Dr. Shizuo Akira and Dr. Kiyoshi Takeda (Osaka University) and crossed
with CD4-Cre mice to generate Stat3 deletion in T cells (Stat3/). Trans-
genic mice expressing human S1pr1 under the control of the human
CD2 promoter (S1pr1-Tg) were kindly provided by Dr. Markus Gra¨ler (Hann-
over Medical School). S1pr1-Tg mice were crossed with the CD4-Cre/
Stat3loxp/loxp mice to generate mice with S1pr1-Tg/Stat3/ T cells.
Foxp3-GFP knockin mice were obtained from Dr. Defu Zeng (City of
Hope) and subsequently crossed with S1pr1-Tg mice. C57BL/6 mice were
purchased from the National Cancer Institute. Rag1/ and Rag2/ mice
were obtained from the Jackson Laboratory. Mouse care and experimental
procedures were performed in accordance with established institutional
guidance and approved protocols from Institutional Animal Care and UseCommittee at the Beckman Research Institute of City of Hope National
Medical Center.
In Vivo Tumor Studies
The B16 mouse melanoma cell line was obtained from American Type Cul-
ture Collection and maintained in RPMI-1640 medium containing 10% fetal
bovine serum (FBS). The MB49 mouse bladder carcinoma line was kindly
provided by J. Fidler (MD Anderson Cancer Center) and maintained in
Dulbecco’s modified Eagle’s medium (DMEM) containing 10% FBS. For
the B16 and MB49 tumor models, 1 3 105 or 5 3 105 cells were subcuta-
neously injected into 8–10 weeks old C57BL/6, Rag1/, or Rag2/ mice.
The E0771 mouse breast cancer cell line was kindly provided by Dr. An-
dreas Moeller (Peter MacCallum Cancer Centre) and maintained in DMEM
containing 20% FBS. For the E0771 tumor model, 1 3 105 E0771 cells
were orthotopically injected into the fourth mammary fat pad of 8–10 weeks
old female C57BL/6 mice. Tumor volumes were measured every other day,
and mice were euthanized once the control tumors reached approximately
1,000 mm3.Cell Reports 6, 992–999, March 27, 2014 ª2014 The Authors 997
For adoptive T cell transfer, WT, S1pr1-Tg, Stat3/, and S1pr1-Tg/Stat3/
CD4+ T cells as well asWT and S1pr1-TgCD8+ T cells were positively enriched
using MACS cell separation kits (Miltenyi Biotec). Enriched T cells (5 3 106)
were retro-orbitally injected into 8–10 weeks old Rag1/ mice, which were
subcutaneously implanted with 13 105 B16 cells 1 week later. For coadoptive
T cell transfer, WT andS1pr1-Tg splenic T cells were enriched usingMACS cell
separation, and 23 106 cells were retro-orbitally injected into 8–10 weeks old
Rag2/mice, which were subcutaneously implanted with 53 105 MB49 cells
1 day later. For in vivo treatment with FTY720 (synthesized by the Synthetic
and Biopolymer Chemistry Core at City of Hope), 8–10 weeks old Foxp3-
GFP mice were subcutaneously implanted with 5 3 105 B16 cells and were
retro-orbitally injected with 200 ml PBS containing 2.5% DMSO alone or
50 mg FTY720 in 2.5% DMSO once tumors reached 300–500 mm3 in size.
Mice were euthanized 24 hr later, and tissues were collected for further
analysis.
In Vitro T Cell Migration
Migration assays were carried out using the Corning HTS Transwell 96-well
permeable support system with 5.0 mm pore size polycarbonate membrane.
The bottom wells were filled with 200 ml migration buffer alone (RPMI-1640
medium with 0.1% fatty acid-free BSA and 10 mM HEPES) or migration buffer
containing either 10 nM S1P (Sigma-Aldrich) or 20% B16 TCM. To prepare
B16 TCM, single-cell suspensions from B16 tumors grown in WT mice
were plated at 1 3 106/ml in serum-free RPMI-1640 media for 24 hr (Deng
et al., 2012). Media was collected, 0.22 mm filtered, aliquoted, and stored
at 80C. To deplete lipids, TCM was incubated with dextran-coated char-
coal (T-70; Sigma) at 10 mg/ml for 30 min. Total splenocytes harvested
from tumor-bearing mice were stained with allophycocyanin (APC)-CD3 and
phycoerythrin (PE)-CD4 antibodies. Cells were then washed three times and
resuspended in migration buffer to a final concentration of 1 3 107/ml.
In some experiments, cells were then incubated with or without 5 mM
AZD1480 (AstraZeneca) at 37C for 30 min. Then, 50 ml of cells was added
into each top well and allowed to migrate at 37C for 1 or 2 hr. Migrated cells
were fixed, permeabilized, and stained with fluorescein isothiocyanate (FITC)-
Foxp3 antibody, and migrated cells in the bottom wells were counted by flow
cytometry (Accuri; BD Biosciences). Triplicates were performed for each
condition.
Intracellular Staining and Flow Cytometry
To prepare single-cell suspensions for flow cytometry, tumor tissue was
dissected into approximately 1–5 mm3 fragments and digested with collage-
nase Type D (2 mg/ml; Roche) and DNase I (1 mg/ml; Roche) for 30–45 min
at 37C. Digests were filtered through 70 mm cell strainers, pelleted
(1,500 rpm for 5 min), and, for B16 tumors, immune cells were enriched from
tumor digests using Histopaque-1083 (Sigma-Aldrich). Spleens and lymph
nodes were gently dissociated under 70 mmmesh for single-cell isolation. After
red blood cell lysis (Sigma-Aldrich), single-cell suspensions were filtered,
washed, and resuspended in FACS Wash Buffer (2% FBS in Hank’s balanced
salt solution without Ca, Mg, and phenol red). Cells were blocked with CD16/
CD32 and incubated for 30 min on ice with fluorescein isothiocyanate-,
phycoerythrin-, APC-, peridinin chlorophyll protein-Cy5.5-, PE-Cy7-, Alexa
Fluor-700, Pacific Blue, and APC-Cy7 (or Alexa Fluor-e780)-conjugated anti-
bodies (CD3, CD4, CD8, CD62L, CD69, IFNg, and granzyme B) purchased
from Biolegend, eBioscience, or BD Bioscience. FITC-Foxp3 antibody was
purchased from eBioscience. Aqua LIVE/DEAD used for cell viability was pur-
chased from Invitrogen. Cells were washed twice before analysis on the BD
LSR Fortessa flow cytometer (Beckman Coulter Genomics).
For intracellular staining, cells were fixed and permeabilized using the
Foxp3 Fixation/Permeabilization kit (eBioscience) according to manufac-
turer’s protocol. Following two washes, cells were stained for 30 min on
ice with fluorophore-conjugated antibodies. For intracellular pSTAT3, cell-
surface-marker-stained cells were fixed with 2% paraformaldehyde and
permeabilized with 20C methanol, blocked with mouse serum, and incu-
bated at ambient room temperature for 30 min with Alexa Fluor-647 anti-
phospho-STAT3 (pSTAT3; Y705), purchased from BD Biosciences. Cells
were washed twice before flow cytometric analysis. Cell sorting was per-
formed on the BD FACS Aria-III (or Aria-III SORP) high-speed cell sorter using998 Cell Reports 6, 992–999, March 27, 2014 ª2014 The Authorsfluorophore-conjugated antibodies with DAPI (Sigma-Aldrich) for viability.
Data were analyzed with FlowJo software (Tree Star).
Real-Time Quantitative PCR
Tumor-infiltrating CD8+ T cells were FACS sorted from E0771 tumor-bearing
WT and S1pr1-Tgmice. RNAwas extracted using column purification (Ambion
RNAqueous Micro kit). cDNA was prepared using Bio-Rad cDNA synthesis kit
(Bio-Rad). RT-PCRwas performed using Bio-Rad SYBRGreen Supermix (Bio-
Rad). Primers were generated using SciTools (Integrated DNA Technologies)
and PubMed blasted for gene and species specificity. Each primer set was
validated using a standard curve across the dynamic range of interest with a
single melting peak.
Western Blotting
For western blotting, CD4+ T cells were positively enriched using the EasySep
cell isolation kit (STEMCELL Technologies). In some experiments, enriched
cells were cultured in RPMI-1640 medium containing 2% FBS with or without
20% B16 TCM at 37C. Cells were lysed in 1% Nonidet P-40 lysis buffer
containing protease inhibitor cocktail (Sigma-Aldrich) and 1mM sodium ortho-
vanadate (Sigma-Aldrich). Protein lysates (5–20 mg) were subjected to SDS-
PAGE, probed with indicated antibodies, and detected using an enhanced
chemiluminescence substrate (Pierce). Polyclonal antibodies against STAT3
and S1PR1 were purchased from Santa Cruz Biotechnology. Monoclonal
b-actin antibody was purchased from Sigma-Aldrich. Phospho-STAT3
(Y705) antibody was purchased from Cell Signaling Technology.
Statistical Analysis
Data are presented as mean ± SEM, unless otherwise stated. Statistical com-
parisons between groups were performed using the unpaired two-tailed
Student’s t test to calculate p value. *p < 0.05, **p < 0.01, ***p < 0.001; ns,
not significant.
SUPPLEMENTAL INFORMATION
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